


Skin Disease-Oriented Team

Clinical Research Treatment Flowchart

Clinical Research Manager:
Mehir Tharani

Clinical Research Coordinators:
Bao-An Huynh
Natalie Arechiga
Erin Palmer-Torrison
Anastasiia Reipolska





BASKET PHASE I TRIALS

UCI 23-148
CJRB-101 (*L. mesenteroides*) +
Pembro
PI: Nagasaka
CRC: J. Choe
Accrual: 3/6
Accrual pause until ~July 2025



NON INTERVENTIONAL TRIALS

UCI 19-135

DecisionDx-Melanoma Impact on Sentinel Lymph Node Biopsy Decisions and Clinical Outcomes (DECIDE)

PI: Yamamoto
CRC: Anastasiia R.
Accrual: 95/110

UCI 23-149

Multiphoton Microscopy Imaging as a Tool to Monitor Immune Activation Induced by Checkpoint Inhibitors

PI: Ganesan
Contact: Hira Rizwi
Accrual: 5/15

UCI 23-93

Assessment of ICOS as a Novel Biomarker to Determine Response and Resistance of Checkpoint Immunotherapy for Cutaneous Malignancies

PI: Tran
Target Accrual: 0/15



RECURRENT

ETCTN 10592
M1774 +/- avelumab
PI: Gao
CRC: N. Arechiga
Accrual: 3/6

■ Open to Accrual ■ Low Accruing ■ Pending Activation/Suspended



LOCALLY ADVANCED cSCC W/ PREVIOUS CPI

UCI 25-127

L19IL2 + L19TNF (Intratumoral)

PI: Yamamoto

CRC: TBD

Accrual: 0/5

■ Open to Accrual

■ Low Accruing

■ Pending Activation/Suspended



INTERVENTIONAL TRIALS

UCI 23-153

Topical HT-001 for Skin Toxicities
w/EGFR Inhib.
PI: Smith
CRC: B. Huynh
Accrual: 2/16

UCI 25-08

Laser treatment for Stage 1 BCC
PI: Zachary
CRC: TBD
Accrual: 0/20

UCI 25-57

Neoadjuvant Opdualag vs. Nivolumab
for Resectable High-Risk BCC
PI: Vaidya
CRC: TBD
Accrual: 0/5

UCI 25-127

Biofield therapy for immunotherapy-
related symptoms
PI: Kagramanov
CRC: TBD
Accrual: 0/10

NON-INTERVENTIONAL TRIALS

UCI 11-30

(IRB 2008-6307)
Skin Imaging with Technologies in
Development
PI: Kelly
Accrual: 638/750

UCI 13-13

(IRB 2011-8494)
In-Vivo Non-Invasive Skin Imaging
Using Multiphoton Microscopy and
Multispectral Imaging
PI: Kelly
Accrual: 213/250

UCI 25-68

Understanding Barriers to Skin
Cancer in AAPI
PI: Tran
CRC: TBD
Accrual: 0/10